600645.SS
600645.SS
CNE000000545
VCANBIO CELL & GENE ENG CORP LT
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±40.1% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (-0.1x).

Beta (Market Relation)
-0.1x
Defensive
Volatility (5Y p.a.)
40.1% p.a.
5-Year Horizon
Max Drawdown (5Y)
-53.3%
5-Year Horizon
Sharpe Ratio
-0.17
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -22%
3 Years 42.9% -49.2% -0.02 +1.7%
5 Years 40.1% -53.3% -0.17 -3.9%
10 Years 42.3% -60.6% -0.19 -5.4%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 73.5 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -60.6% in the extended horizon.
ende